Although the federal government is reluctant to publicly announce that marijuana has any clear medical benefit, it has not stopped federal health agencies from supporting manufactured adaptations of the herb’s psychoactive part to be utilized by Big Pharma as a part of the treatment of debilitating conditions. Truth be told, the U.S. Food and Drug Administration (FDA), one of the essential obstructions in the fantastic plan of across the country sanctioning, as of late endorsed a fluid assortment of manufactured tetrahydrocannabinol (THC) that will be sold to individuals experiencing AIDS and cancer.
It was uncovered not long ago that Insys Therapeutics is preparing to pursue a bit of the restorative weed market, one purportedly worth countless dollars, with another FDA-affirmed type of dronabinol. This first-of-a-kind fluid THC engineered, set to be loaded on drug store racks under the name Syndros, has been given the green light for the treatment of “anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.”
Although dronabinol, which is commonly referred to under its brand name Marinol, is nothing new to the pharmaceutical industry’s clever approach to capitalizing on marijuana; the latest version is an “easy-to-swallow” liquid designed for quicker absorption than its pill counterpart. A press release issued by Insys indicates that the drug company plans to convert the majority of its dronabinol business over to Syndros by meeting with nearly 8,000 physicians to discuss the benefits of the updated product.
Of course, this laboratory creation has the advantage over the cannabis products being sold in conjunction with state medical marijuana programs because it comes with a Schedule III classification under the Controlled Substances Act—suggesting both medicinal value and a low risk for abuse. The cannabis plant, however, is still ranked with heroin under Schedule I—a classification that deems the herb as having no medical value and a high risk for abuse.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
